Your browser doesn't support javascript.
loading
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Hepner, Adriana; Versluis, Judith M; Wallace, Roslyn; Allayous, Clara; Brown, Lauren Julia; Trojaniello, Claudia; Gerard, Camille Lea; Jansen, Yanina Jl; Bhave, Prachi; Neyns, Bart; Haydon, Andrew; Michielin, Olivier; Mangana, Joanna; Klein, Oliver; Shoushtari, Alexander N; Warner, Allison Betof; Ascierto, Paolo Antonio; McQuade, Jennifer Leigh; Carlino, Matteo S; Zimmer, Lisa; Lebbe, Celeste; Johnson, Douglas B; Sandhu, Shahneen; Atkinson, Victoria; Blank, Christian U; Lo, Serigne N; Long, Georgina V; Menzies, Alexander M.
Affiliation
  • Hepner A; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Instituto do Cancer do Estado de Sao Paulo, SP, Brazil.
  • Versluis JM; Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
  • Wallace R; Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia.
  • Allayous C; Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, INSERM U976, F-75010 Paris, France.
  • Brown LJ; Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Trojaniello C; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Gerard CL; Precision Oncology Center Oncology department, Lausanne University Hospital CHUV, Lausanne, Switzerland.
  • Jansen YJ; Department of Thoracic Surgery, University Hospitals Leuven, Leuven 3000, Belgium.
  • Bhave P; Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Alfred Health, Melbourne, Australia.
  • Neyns B; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Haydon A; Department of Medical Oncology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia.
  • Michielin O; Precision Oncology Center Oncology department, Lausanne University Hospital CHUV, Lausanne, Switzerland.
  • Mangana J; University Hospital Zürich, Zürich, Switzerland.
  • Klein O; Olivia Newton-John Cancer Centre and Austin Health, Melbourne, Australia.
  • Shoushtari AN; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
  • Warner AB; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • McQuade JL; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Carlino MS; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zimmer L; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Lebbe C; Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, INSERM U976, F-75010 Paris, France.
  • Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.
  • Sandhu S; Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
  • Atkinson V; University of Queensland and Princess Alexandra and Greenslopes Private Hospital, Brisbane, Australia.
  • Blank CU; Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands; Leiden University Medical Center (LUMC), Leiden, the Netherlands.
  • Lo SN; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Long GV; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, NSW, Australia.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, NSW, Australia. Electronic address: alexander.menzies@sydney.edu.au.
Eur J Cancer ; 196: 113441, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37988842
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Melanoma Limits: Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2024 Type: Article Affiliation country: Brazil
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Melanoma Limits: Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2024 Type: Article Affiliation country: Brazil